{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:03:05Z","timestamp":1782370985119,"version":"3.54.5"},"reference-count":39,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2019,11,2]]},"DOI":"10.1080\/13696998.2019.1652183","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T13:15:50Z","timestamp":1564751750000},"page":"1162-1170","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK"],"prefix":"10.1080","volume":"22","author":[{"given":"Miriam","family":"Tarallo","sequence":"first","affiliation":[{"name":"Inflammation and Immunology, Pfizer, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Onishchenko","sequence":"additional","affiliation":[{"name":"McCann Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatia T.","family":"Alexopoulos","sequence":"additional","affiliation":[{"name":"McCann Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,9,9]]},"reference":[{"key":"CIT0001","unstructured":"European Medicines Agency. European Medicines Agency recommends approval of first two monoclonal antibody biosimilars. Recommendation marks extension of biosimilar concept to new product-class; 2013 [cited 2018 Dec 13]. Available from: https:\/\/www.ema.europa.eu\/documents\/press-release\/european-medicines-agency-recommends-approval-first-two-monoclonal-antibody-biosimilars_en.pdf."},{"key":"CIT0002","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) (EMA\/CHMP\/BWP\/247713\/2012); 2014 [2014 May 22]."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2018.77975"},{"key":"CIT0004","unstructured":"European Medicines Agency. Medicines, etanercept. [cited 2018 Dec 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines?search_api_views_fulltext=etanercept."},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190147"},{"key":"CIT0006","unstructured":"CADTH Environmental Scan. International policies on the appropriate use of biosimilar drugs; 2018 [cited 2019 June 10]. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/es0333_international-policies-on-use-of-biosimilar-drugs.pdf."},{"key":"CIT0007","unstructured":"NICE. ETANERCEPT; 2010 [cited 2018 Nov 27]. Available from: https:\/\/bnf.nice.org.uk\/medicinal-forms\/etanercept.html."},{"key":"CIT0008","unstructured":"IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines: the role of functioning competitive markets. 2016. [cited 2018 Mar 8]. Available from: https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2016\/03\/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-eular.1387"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.03.1465"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(15)32893-6"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1375903"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.03.005"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.893241"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1142448"},{"key":"CIT0016","first-page":"3505","volume":"69","author":"Dyball S","year":"2017","journal-title":"Arthritis Rheum"},{"key":"CIT0017","first-page":"1727","volume":"77","author":"Lee SY","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"CIT0018","first-page":"3570","volume":"69","author":"Hendricks O","year":"2017","journal-title":"Arthritis Rheum"},{"key":"CIT0019","first-page":"3488","volume":"69","author":"Tweehuysen L","year":"2017","journal-title":"Arthritis Rheum"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.947"},{"key":"CIT0021","first-page":"488","volume":"69","author":"Alten R","year":"2017","journal-title":"Arthritis Rheum"},{"key":"CIT0022","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/annrheumdis-2017-212767","volume":"77","author":"Alten R","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"CIT0023","unstructured":"Market Research Society. MRS code of conduct; 2014 [cited 2018 Mar 8]. Available from: https:\/\/www.mrs.org.uk\/pdf\/mrs%20code%20of%20conduct%202014.pdf."},{"key":"CIT0024","unstructured":"York Health Economics Consortium. Cohort models; 2016 [cited 2019 June 18]. Available from: https:\/\/www.yhec.co.uk\/glossary\/cohort-models\/."},{"key":"CIT0025","unstructured":"Department of Health and Social Care. NHS reference costs 2015 to 2016. National schedule of reference costs: the main schedule; 2016 [cited 2018 December 4]. Available from: https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2015-to-2016."},{"key":"CIT0026","unstructured":"Curtis LA, Burns A. Unit costs of health and social care 2017; 2017 [cited 2018 Dec 4]. Available from: https:\/\/kar.kent.ac.uk\/65559\/."},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213474"},{"key":"CIT0028","first-page":"97","volume":"37","author":"Gibofsky A","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00322"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.763812"},{"key":"CIT0031","unstructured":"NHS England. NHS set to save \u00a3150 million by switching to new versions of most costly drug; 2018 [cited 2018 Dec 10]. Available from: https:\/\/www.england.nhs.uk\/2018\/10\/nhs-set-to-save-150-million-by-switching-to-new-versions-of-most-costly-drug\/."},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.1547"},{"key":"CIT0033","first-page":"A639","volume":"18","author":"Ruff L","year":"2015","journal-title":"Value Health"},{"key":"CIT0034","first-page":"A639","volume":"18","author":"Ruff L","year":"2015","journal-title":"Value Health"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1159\/000449088"},{"key":"CIT0036","first-page":"A1712","volume":"77","author":"Valido A","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key075.330"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.4236\/ojepi.2015.53020"},{"key":"CIT0039","first-page":"378","volume":"22","author":"Yu B","year":"2016","journal-title":"Am J Manag Care"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2019.1652183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T10:52:10Z","timestamp":1598698330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2019.1652183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,9]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,2]]}},"alternative-id":["10.1080\/13696998.2019.1652183"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2019.1652183","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}